Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (29581)	12/13/1999 1:07:00 AM
From: Cheryl Galt	Respond to of 32384

From Daily Summaries from ASH - Day 3 "The study [Ligand's, Targretin for early-stage CTCL] is an important one, suggesting the possibility of a new treatment modality in patients with CTCL who have failed prior treatments. " ----------------------------- 41st American Society of Hematology Annual Meeting Day 3 - December 6, 1999 What's New With "Standard" Chemotherapy for Lymphoma? Alexandra M. Levine, MD A very interesting oral session was conducted today, concerning new treatment modalities for patients with various types of lymphoma. This session included primarily research on standard chemotherapeutic agents, although some work related to antibody therapy for T-prolymphocytic leukemia was also presented. Cutaneous T Cell Lymphoma (CTCL) The use of bexarotene (Targretin), a novel RXR-selective retinoid, was studied in 58 patients with CTCL who were refractory, intolerant, or no longer responding to at least two prior therapies for their disease.[1] Patients had received a median of 3.5 (range 2-13) prior therapies. In this trial, patients either received 6.5 mg/m2 or 650 mg/m2 orally, once per day. The 650-mg/m2 dose was subsequently decreased to 500 mg/m2, and then to an optimum dose of 300 mg/m2/day. Taking all doses together, the overall response rate to bexarotene was 48% (28/58). A dose-response relationship was seen, with a 20% response at 6.5 mg, 54% at 300 mg, and 67% response when doses higher than 300 mg were employed. The median time to first response was 57 days at 300 mg/m2. Median time to best response was 87 days (range, 27-153). At the dose of 300 mg/m2, the median duration of response ranged from 120-210 days. A total of 13% of responders have relapsed. Toxicities included hyperlipemia (71%), hypercholesteremia (36%), headache (36%), hypothyroidism (29%), leukopenia (18%), pruritis (18%), and nausea (18%). The study is an important one, suggesting the possibility of a new treatment modality in patients with CTCL who have failed prior treatments. ---------------------------------------------------------------- Index of 12/99 ASH summaries medscape.com